12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Company News  |  Deals

Bind Therapeutics, Pfizer deal

Bind (formerly Bind Biosciences Inc.) and Pfizer partnered to develop and commercialize Accurins using undisclosed small molecules provided by the pharma for undisclosed diseases. Accurins are selective and programmable...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >